 |
|
Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease)
Bianca Weinstock-Guttman, MD;
Murali Ramanathan, PhD;
Norah Lincoff, MD;
Salvatore Q. Napoli, MD;
Jitendra Sharma, MD;
Joan Feichter, RN;
Rohit Bakshi, MD
Arch Neurol. 2006;63:957-963.
Background Neuromyelitis optica is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. It is considered to have a B-cell–induced pathogenesis. Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, has been shown to primarily suppress the humoral response.
Objective To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica.
Design Prospective 2-year study.
Setting Academic multiple sclerosis center.
Patients Five patients (3 women and 2 men) with an age range of 20 to 51 years and an Expanded Disability Status Scale score of 2.5 to 6.5 (mean ± SD, 4.40 ± 1.88).
Interventions Monthly intravenous infusions of mitoxantrone hydrochloride, 12 mg/m2, for 6 months followed by 3 additional treatments every 3 months.
Main Outcome Measures Expanded Disability Status Scale score measured every 3 months and during relapses; findings on orbital, brain, and spinal cord magnetic resonance images performed at baseline and at 3, 6, 12, 18, and 24 months; and visual evoked potentials and results of ophthalmologic evaluations performed at baseline and annually.
Results During the 2 years of treatment, 2 patients each had a relapse once within the initial 5 months of treatment (1 severe and 1 moderate). Improvement was seen clinically and on magnetic resonance images in 4 patients. Patients generally tolerated the treatment well, although 1 patient had a reversible decrease in cardiac ejection fraction.
Conclusion Our results suggest a beneficial effect of mitoxantrone treatment for relapsing neuromyelitis optica.
Trial Registration clinicaltrials.gov Identifier: NCT00304291
Author Affiliations: The William C. Baird Multiple Sclerosis Center, Jacobs Neurological Institute (Drs Weinstock-Guttman, Ramanathan, and Lincoff and Ms Feichter) and Department of Pharmaceutical Sciences (Dr Ramanathan), State University of New York, Buffalo; and Partners Multiple Sclerosis Center, Center for Neurological Imaging, Departments of Neurology and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Drs Napoli, Sharma, and Bakshi).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Relapsing neuromyelitis optica: long term history and clinical predictors of death
Cabre et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:1162-1164.
ABSTRACT
| FULL TEXT
Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis
Green and Cree
J. Neurol. Neurosurg. Psychiatry 2009;80:1002-1005.
ABSTRACT
| FULL TEXT
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Jacob et al.
Arch Neurol 2009;66:1128-1133.
ABSTRACT
| FULL TEXT
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder
Bonnan et al.
Mult Scler 2009;15:487-492.
ABSTRACT
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
Jacob et al.
Arch Neurol 2008;65:1443-1448.
ABSTRACT
| FULL TEXT
Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica
Weinstock-Guttman et al.
Mult Scler 2008;14:1061-1067.
ABSTRACT
Review: Treatment of neuromyelitis optica: Current debate
Okamoto et al.
Therapeutic Advances in Neurological Disorders 2008;1:43-52.
ABSTRACT
Is Neuromyelitis Optica Eyeing a Distinct Path From Multiple Sclerosis?
Glisson and Galetta
Arch Ophthalmol 2008;126:128-129.
FULL TEXT
|
